ETHAMOLIN
LOE Approachingethanolamine oleate
NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
ETHAMOLIN (ethanolamine oleate) is clinical pharmacology when injected intravenously, ethamolin injection acts primarily by irritation of the intimal endothelium of the vein and produces a sterile dose-related inflammatory response. Approved for to prevent rebleeding, hypertension. First approved in 1988.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ETHAMOLIN (ethanolamine oleate) is an injectable sclerosing agent that acts by irritating the venous endothelium to produce inflammation, fibrosis, and vein occlusion. It is indicated to prevent rebleeding from esophageal varices and has been used off-label for hypertension management. The oleic acid component drives the inflammatory cascade while ethanolamine may inhibit coagulation.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100) suggests consolidating team focus on retention and transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY When injected intravenously, ETHAMOLIN Injection acts primarily by irritation of the intimal endothelium of the vein and produces a sterile dose-related inflammatory response. This results in fibrosis and possible occlusion of the vein. ETHAMOLIN Injection also rapidly…
Indications (2)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.